Impact of Preoperative Urine Culture Following Transurethral Resection of the Prostate (UROCULTURP). (UROCULTURP)

November 10, 2026 updated by: Francisco Luis Caro Zapata, Universidad de Antioquia

Impact of Preoperative Urine Culture on the Prevention of Postoperative Urinary Tract Infections Following Transurethral Resection of the Prostate in Men With Benign Prostatic Hyperplasia: Protocol for a Multicenter, Parallel-group, Randomized Non-inferiority Diagnostic Test Trial.

Benign prostatic hyperplasia (BPH) is a common condition in men, and a proportion of affected patients require surgical treatment. Transurethral resection of the prostate (TURP) is considered the gold standard for the surgical management of these patients. Preoperative asymptomatic bacteriuria (ASB) is present in approximately 30% of patients with BPH undergoing TURP. Current guidelines recommend screening for and treating ASB before endoscopic urological procedures associated with mucosal trauma to prevent postoperative infectious complications. However, the precise role of ASB in the development of postoperative urinary tract infections (UTIs) remains unclear, and the quality of the evidence supporting these recommendations is low.

A prospective, comparative clinical study is therefore warranted to determine the effectiveness of preoperative screening for and treatment of ASB in preventing infectious complications in patients with BPH undergoing TURP. The findings may help address existing knowledge gaps, inform future recommendations, and promote adherence to evidence-based clinical decision-making.

The objective of this study is to determine the effectiveness of preoperative screening for and treatment of ASB in preventing postoperative infectious complications in patients with BPH undergoing TURP.

A multicenter, parallel-group, randomized non-inferiority diagnostic test trial is proposed. A total of 1,262 men aged over 45 years with a diagnosis of BPH, an indication for TURP due to BPH, and no signs or symptoms of UTI will be enrolled. Participants will be randomly assigned in a 1:1 ratio to one of two groups according to whether the results of the preoperative urine culture are disclosed or withheld. Participants will be followed up for one month, and the primary outcome will be the occurrence of urinary tract infection (UTI).

The study was approved for review by the Research Ethics Committee of the Faculty of Medicine at the University of Antioquia and by the ethics committees of all participating institutions involved in patient recruitment.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

1262

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Antioquia
      • Medellín, Antioquia, Colombia
        • Hospital Alma Mater de Antioquia
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Men aged >45 years with a diagnosis of benign prostatic hyperplasia (BPH).
  • Indication for transurethral resection of the prostate (TURP) for BPH.
  • Absence of signs or symptoms of urinary tract infection (UTI).

Exclusion Criteria:

  • Symptomatic urinary tract infection (UTI) or antibiotic treatment within the previous month for a UTI or any other infectious condition.
  • Patients scheduled to undergo additional transurethral procedures during the same surgical session (e.g., urethrotomy, transurethral resection of a bladder tumor [TURBT], or cystolithotomy).
  • Diagnosis of prostate cancer.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Disclosure Group

Disclosure of preoperative urine culture results

In this arm, the results of the preoperative urine culture will be made available to the treating urologist.

Other: Non-Disclosure Group

Non-disclosure of preoperative urine culture results

In this arm, the results of the preoperative urine culture will not be made available to the treating urologist.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Urinary tract infection (UTI)
Time Frame: 30 days or 1 month

UTI was defined according to the American Urological Association (AUA) antimicrobial prophylaxis guidelines (43), supplemented by the European Association of Urology (EAU) UTI diagnostic criteria (10). Patients were classified as having a UTI if they met any of 4 scenarios:

(1) ≥1 urinary symptom or fever, positive urine culture (>10⁵ CFU), and surgeon-confirmed post-endoscopic UTI; (2) ≥2 urinary symptoms or fever plus supportive laboratory findings or clinical diagnosis; (3) postoperative fever with imaging suggestive of pyelonephritis after TURP, or catheter-associated UTI with ≥10³ CFU/mL within the specified catheterization period; or (4) ≥2 persistent urinary symptoms for >1 week after catheter removal, without fever or improvement, plus positive urine culture (>10⁵ CFU) and surgeon-confirmed post-endoscopic UTI.

30 days or 1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Urinary sepsis
Time Frame: 30 days or 1 month

Patients will be diagnosed with rrinary sepsis if they meet the criteria:

  • The patient has a recognized pathogen cultured from one or more blood culture specimens; AND
  • The organism isolated from the blood is not associated with an infection at another site; AND
  • The patient presents with at least one of the following signs or symptoms: fever (>38 °C), chills, hypotension or septic shock, or organ dysfunction; AND
  • The signs and symptoms, as well as the positive laboratory findings, are not attributable to an infection at another site.

In clinical practice, organ dysfunction may be indicated by a Quick Sequential Organ Failure Assessment (qSOFA) score of ≥2. The qSOFA criteria are a respiratory rate of ≥22 breaths/min, altered mental status, or systolic blood pressure of ≤100mmHg.

Septic shock will be defined as the requirement for vasopressors to maintain a mean arterial pressure of ≥65 mmHg, together with a serum lactate level of >2 mmol/L(>18 mg/dL), in the absence of hypovolemia

30 days or 1 month
Acute orchiepididymitis
Time Frame: 30 days or 1 month

Acute orchiepididymitis will be defined as the presence of scrotal pain, swelling, increased temperature, and inflammatory changes, accompanied by testicular and/or epididymal tenderness and enlargement on palpation; or inflammatory changes involving the testis and/or epididymis, with increased blood flow on color Doppler ultrasonography, with or without intratesticular collections on ultrasound examination. These findings may occur regardless of whether the urine culture is positive.

30 days or 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Francisco L Caro, MD, Urologist, Universidad de Antioquia
  • Study Director: Ivan D Florez, MD, MSc, PhD, Universidad de Antioquia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

November 1, 2029

Study Completion (Estimated)

June 1, 2030

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SIIU2024-78410
  • IN70-2024 (Other Identifier: Hospital Alma Mater de Antioquia)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.